Two meta-analyses of clinical trials comparing anti-PD-1 or anti-PD-L1 to docetaxel demonstrated that patients with EGFR mutant NSCLC did not benefit from ICIs treatment as their wild-type counterparts [8, 9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.